🧵 Many PKD International members from around the world joined the Novartis ADPKD Advisory Board in Glasgow on 2 June to discuss patient needs, clinical trials, research access, and health equity.
✨ Only one day to go until #ERA2026 !
We are looking forward meeting, clinicians, researchers. Come and talk to our members — we would be delighted to meet you and answer your questions. 💛
📍 Glasgow & Virtual
🗓️ 3–6 June 2026
🤝 Visit us at Booth 2, Hall 5
@ERAkidney
🧵 (3/3) 📘 This recipe is taken from “Flavors that Nourish”, a recipe book inspired by holistic health for people with PKD, created by Riñón Poliquístico de México A.C. and authored by Ana Sofia López and L.N. Ari Cisneros.
🧵 🥑 PKD & Food | Avocado Toast
A balanced diet can play an important role in the day-to-day management of Polycystic Kidney Disease (PKD). Through our nutrition series, we continue to share simple and flavourful recipes that support more informed food choices.
🧵(2/3) 🌅 This time, we start with breakfast — featuring a classic: Avocado Toast. Easy to prepare, nutritious, and versatile, it’s an ideal way to begin the day with fresh ingredients and balanced flavours.
🧵💙 ERA Congress 2026 | Glasgow & Virtual
From June 3–6, 2026, Glasgow will host the 63rd ERA Congress, one of the leading international events in nephrology, research, and kidney health.
🧵 (2/3) 🌍 PKD International looks forward to meeting patients, clinicians, researchers, and scientists from around the world. Unless we are attending PKD sessions, you will find us at our booth throughout the congress.
🤝 Visit us at Booth number 2 in Hall 5
🧵 (4/4) This survey is designed to capture those perspectives — helping researchers identify key needs, improve how data is used, and ensure that future tools and studies are developed responsibly and with patients at the centre.
📲 https://t.co/aHBWz9PgNc
🧵 (4/4) Led by the University of Cologne, STOP-PKD aims to explore whether this treatment could help slow disease progression and offer new options for patients. A clear sign of growing collaboration and progress across Europe.
@FLAVIAZH@MuellerRom@UKKoeln@Nierstichting
🧵🧪 STOP-PKD study | Expanding recruitment across Europe : https://t.co/OntDB0Jp8z
The STOP-PKD study continues to expand, marking an important step forward for ADPKD research in Europe.
🧵 (3/4) The study focuses on dapagliflozin, an SGLT2 inhibitor already used in other kidney diseases, but not previously studied in people living with ADPKD.
PKD International was delighted to attend the ERKNet Annual Meeting in Lyon, contributing the patient voice in 2 WGs and participating in valuable discussions on clinical trial readiness and collaboration for rare kidney diseases across Europe.
#RareKidneyDiseases#ADPKD#ARPKD
I usually think twice before posting preprints. But this time it’s different.
MEDA-PKD is the essence of our work over more than a decade — and, to me, one of the most meaningful contributions I’ve been able to make to biomedical research.
🧵